WOBURN, Mass.--(BUSINESS WIRE)--VisEn Medical, Inc. today announced that it has entered into a joint research program to expand the capabilities and accelerate the adoption of VisEn’s in vivo fluorescence technologies in Eli Lilly and Company’s research and development programs. Lilly has been working with VisEn’s portfolio of in vivo fluorescence probes and Fluorescence Molecular Tomography (FMT™) imaging systems as part of their new molecular imaging center and preclinical development programs. This research program is intended to further the development and expand the application of VisEn’s leading fluorescence in vivo imaging technologies in pharmaceutical drug development.
